SG11202103373QA - LEUCINE-RICH α2 GLYCOPROTEIN COMPOSITION - Google Patents

LEUCINE-RICH α2 GLYCOPROTEIN COMPOSITION

Info

Publication number
SG11202103373QA
SG11202103373QA SG11202103373QA SG11202103373QA SG11202103373QA SG 11202103373Q A SG11202103373Q A SG 11202103373QA SG 11202103373Q A SG11202103373Q A SG 11202103373QA SG 11202103373Q A SG11202103373Q A SG 11202103373QA SG 11202103373Q A SG11202103373Q A SG 11202103373QA
Authority
SG
Singapore
Prior art keywords
leucine
rich
glycoprotein composition
glycoprotein
composition
Prior art date
Application number
SG11202103373QA
Other languages
English (en)
Inventor
Shigeo Takayama
Tetsuji Naka
Satoshi Serada
Original Assignee
Sekisui Medical Co Ltd
National Institutes Of Biomedical Innovation Health And Nutrition
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sekisui Medical Co Ltd, National Institutes Of Biomedical Innovation Health And Nutrition filed Critical Sekisui Medical Co Ltd
Publication of SG11202103373QA publication Critical patent/SG11202103373QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/473—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used alpha-Glycoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
SG11202103373QA 2018-10-09 2019-10-08 LEUCINE-RICH α2 GLYCOPROTEIN COMPOSITION SG11202103373QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018190904 2018-10-09
PCT/JP2019/039565 WO2020075692A1 (ja) 2018-10-09 2019-10-08 ロイシンリッチα２グリコプロテイン組成物

Publications (1)

Publication Number Publication Date
SG11202103373QA true SG11202103373QA (en) 2021-05-28

Family

ID=70165198

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202103373QA SG11202103373QA (en) 2018-10-09 2019-10-08 LEUCINE-RICH α2 GLYCOPROTEIN COMPOSITION

Country Status (7)

Country Link
US (1) US20220127314A1 (ko)
EP (1) EP3865503A4 (ko)
JP (1) JP7421712B2 (ko)
KR (1) KR20210073547A (ko)
CN (1) CN112789288A (ko)
SG (1) SG11202103373QA (ko)
WO (1) WO2020075692A1 (ko)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2718325C2 (de) * 1977-04-25 1986-09-25 Behringwerke Ag, 3550 Marburg Leucinreiches 3,1-S-α↓2↓-Glykoprotein sowie dessen Verwendung
US7416850B2 (en) * 2006-01-25 2008-08-26 Jemmerson Ronald R Cytochrome c and leucine-rich alpha-2-glycoprotein-1 assays, methods and antibodies
JP5422108B2 (ja) * 2007-10-16 2014-02-19 栄研化学株式会社 ヘムタンパク質の安定化方法及び保存溶液
JP5246709B2 (ja) 2009-06-09 2013-07-24 独立行政法人医薬基盤研究所 自己免疫疾患検査用バイオマーカー及び検査方法
EP2462164A2 (en) * 2009-08-04 2012-06-13 Biosystems International SAS Lung cancer biomarkers
JP5717021B2 (ja) 2009-12-03 2015-05-13 独立行政法人医薬基盤研究所 血管新生誘導分子
US9903865B2 (en) 2010-03-31 2018-02-27 Sekisui Medical Co., Ltd. Assay, immunochromatographic test strip, and assay reagent kit for measuring an analyte, using a hematocrit correction
CN102243240B (zh) * 2010-05-11 2014-08-27 中国科学院上海生命科学研究院 非小细胞肺癌分子标志物及其应用
JP6013717B2 (ja) 2010-09-30 2016-10-25 積水メディカル株式会社 液状保存可能なタンパク質溶液及びタンパク質溶液の液状での保存方法
JP6675605B2 (ja) 2014-10-10 2020-04-01 国立大学法人高知大学 細胞遊走調節に関する疾患の予防・治療剤および肺間質の疾患の疾患活動性判定・予後評価
KR20160045547A (ko) * 2014-10-17 2016-04-27 에스케이텔레콤 주식회사 췌장암 진단용 조성물 및 이를 이용한 췌장암 진단방법
KR101853118B1 (ko) * 2016-09-02 2018-04-30 주식회사 바이오인프라생명과학 피험체의 폐암 진단을 위한 복합 바이오마커군, 이를 이용하는 폐암 진단용 키트, 복합 바이오마커군의 정보를 이용하는 방법 및 이를 수행하는 컴퓨팅 시스템
CN110412294B9 (zh) * 2019-08-07 2023-05-26 深圳市新产业生物医学工程股份有限公司 蛋白稳定液、蛋白校准品、试剂盒及检测蛋白校准品稳定性的方法

Also Published As

Publication number Publication date
KR20210073547A (ko) 2021-06-18
US20220127314A1 (en) 2022-04-28
WO2020075692A1 (ja) 2020-04-16
JPWO2020075692A1 (ja) 2021-09-24
CN112789288A (zh) 2021-05-11
EP3865503A1 (en) 2021-08-18
EP3865503A4 (en) 2022-07-13
JP7421712B2 (ja) 2024-01-25

Similar Documents

Publication Publication Date Title
EP3632941C0 (en) RESIN COMPOSITION
ZA201908604B (en) Whitening composition
GB201911800D0 (en) Antiflouling Composition
SG11202012734YA (en) Composition
GB201820878D0 (en) Composition
GB201811100D0 (en) Composition
GB2606975B (en) Composition
GB201804434D0 (en) Composition
GB2583851B (en) Composition
GB201909924D0 (en) Composition
SG11202011204PA (en) Composition
GB201901161D0 (en) Composition
GB201818827D0 (en) Composition
PL3571933T3 (pl) Kompozycja
SG11202103373QA (en) LEUCINE-RICH α2 GLYCOPROTEIN COMPOSITION
SG11202102216QA (en) Polysiloxane composition
SG11202011908YA (en) Delamanid-containing composition
GB201819861D0 (en) Composition
GB201815032D0 (en) Composition
GB201810024D0 (en) Composition
GB201809123D0 (en) Composition
GB201801596D0 (en) Composition
SG11202105131TA (en) Polyamide composition
GB201913398D0 (en) Composition
GB201820082D0 (en) Composition